奈达铂联合5 氟尿嘧啶对晚期食管癌患者CEA及SCC 水平的影响及其临床疗效

目的:探讨奈达铂联合5-氟尿嘧啶对食管癌晚期患者CEA,SCC及临床疗效的影响。方法:收集我院收治的食管癌晚期患者60例,随机分为对照组和实验组,每组各30例,对照组患者给予顺铂+5-氟尿嘧啶的化疗方案,实验组患者给予奈达铂+5-氟尿嘧啶方案化疗。观察并比较两组患者治疗前后血清CEA及SCC水平的变化情况、毒副反应发生率以及临床疗效。结果:与治疗前相比,两组患者治疗后CEA及SCC水平均降低,差异具有统计学意义(P0.05);与对照组相比,实验组患者治疗后CEA及SCC水平较低,差异具有统计学意义(P0.05);与对照组比较,实验组患者毒副反应发生率较低,差异具有统计学意义(P0.05);与对照组比较,实验组患者治疗有效率较高,差异具有统计学意义(P0.05)。结论:奈达铂联合5氟尿嘧啶能够降低食管癌晚期患者CEA、SCC以及毒副反应发生率,提高治疗效果。

Effect of Nedaplatin Combined with 5 Fluorouracil on the Levels of CEA and SCC in Patients with Advanced Esophageal Cancer and its Clinical Efficacy

Objective:To investigate the effect of nedaplatin combined with 5 fluorouracil on the changes of CEA and SCC and its clinical efficacy for patients with advanced esophageal cancer.Methods:60 patients with advanced esophageal cancer who were treated in our hospital were selected and randomly divided into the experiment group and the control group, with 30 cases in each group. The patients in the control group were treated with cisplatin 5-fluorouracil chemotherapy, while the patients in the experiment group were treated with the nedaplatin 5-fluorouracil (5-FU) chemotherapy. Then the changes of CEA and SCC, and the treatment toxic reaction rate and clinical efficacy were observed and compared before and after the treatment.Results:Compared with before treatment, the levels of CEA and SCC in the two groups decreased after the treatment, and the differences were statistically significant (P<0.05); Compared with the control group, the levels of CEA and SCC in the experiment group were lower than those of the control group, and the differences were statistically significant (P<0.05); The toxic reaction rate in the experiment group was lower than that of the control group, and the difference was statistically significant (P<0.05); The clinical efficacy in the experiment group was higher than that of the control group, and the difference was statistically significant (P<0.05).Conclusion:Nedaplatin combined with 5-fluorouracil can reduce the levels of CEA and SCC and the toxic reactions of patients with esophageal cancer, and improve the clinical efficacy.